RxDoctor Payments Data

Chetna Mital

Internal Medicine · Hamilton, OHNPI 1285637694

Payments from drug & device makers

$16,290in general payments, 2019–2025

Across 1,042 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$2K
  • GSK$919
  • Astellas Pharma US Inc$893
  • AbbVie$825
  • Boehringer Ingelheim$793
  • plus $8K from 53 others

What the payments were for

  • Food & beverage$16,00598%
  • Education$2852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca155$2,960
Novo Nordisk108$1,553
GSK63$919
Astellas Pharma US Inc43$893
AbbVie(2 entities)71$825
Boehringer Ingelheim49$793
Lilly USA, LLC49$769
Merck56$767
Amgen40$661
Johnson & Johnson26$481
Amarin Pharma, Inc.27$452
Pfizer45$434
Bayer26$409
Nestle Healthcare Nutrition Inc.43$346
Novartis18$346
Sumitomo Pharma America, Inc.17$329
Exact Sciences17$322
Aimmune Therapeutics, Inc.26$236
Sunovion Pharmaceuticals Inc.15$213
Medtronic(2 entities)12$205
Grifols USA, LLC9$178
E.r. Squibb & Sons, L.L.C.9$139
Xeris Pharmaceuticals, Inc.7$131
Esperion Therapeutics, Inc.7$113
Teva Pharmaceuticals USA, Inc.6$108
Kowa Pharmaceuticals America, Inc.7$105
Biogen6$100
Sanofi-aventis U.S. LLC6$92
Phathom Pharmaceuticals, Inc.4$90
Paratek Pharmaceuticals, Inc.4$88
Mylan Specialty L.p.5$83
Bristol Myers Squibb1$83
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$82
Daiichi Sankyo Inc.5$77
Abbott4$67
Dexcom, Inc.4$62
Pulmonx Corporation3$59
Scilex Pharmaceuticals Inc.4$59
Radius Health, Inc.3$59
Regeneron Healthcare Solutions, Inc.4$56
Insulet Corporation2$49
Otsuka America Pharmaceutical, Inc.3$49
Lundbeck LLC2$48
Evoke Pharma, Inc.3$47
Avanir Pharmaceuticals, Inc.3$40
Nabriva Therapeutics, PLC2$38
Verona Pharma, Inc.1$29
Takeda Pharmaceuticals U.S.A., Inc.2$28
Biohaven Pharmaceuticals, Inc.2$28
Circassia Inc.2$28
Neurocrine Biosciences, Inc.1$25
Eisai Inc.2$24
Inogen, Inc.1$19
Sun Pharmaceutical Industries Inc.1$19
Ultragenyx Pharmaceutical Inc.1$19
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$17
Axsome Therapeutics, Inc.1$17
Ardelyx, Inc.1$15
Biohaven Pharmaceutical Holding Company Ltd.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,290 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$233,110
Medicare patients
361
Services billed
4,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban446$311,872
OzempicSemaglutide134$160,043
JardianceEmpagliflozin166$133,372
Trelegy ElliptaFluticasone/Umeclidin/Vilanter126$108,296
FarxigaDapagliflozin Propanediol93$90,750
TradjentaLinagliptin96$71,816
MyrbetriqMirabegron108$70,389
EntrestoSacubitril/Valsartan83$66,526
JanuviaSitagliptin Phosphate89$61,978
Breztri AerosphereBudesonide/Glycopyr/Formoterol58$52,039
XareltoRivaroxaban91$50,210
JanumetSitagliptin Phos/Metformin Hcl48$36,511
TrulicityDulaglutide34$34,244
Atorvastatin Calcium2,064$31,722
VascepaIcosapent Ethyl48$28,826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$434$311,872446 claims
Boehringer IngelheimJardiance, Tradjenta$793$205,188262 claims
Novo NordiskOzempic, Rybelsus$1,553$186,085147 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$2,960$176,687227 claims
GSKTrelegy Ellipta, Breo Ellipta$919$120,539153 claims
MerckJanuvia, Janumet$767$98,489137 claims
Astellas Pharma US IncMyrbetriq$893$70,389108 claims
NovartisEntresto$346$66,52683 claims
Lilly USA, LLCTrulicity, Mounjaro$769$61,25160 claims
Johnson & JohnsonXarelto$481$50,21091 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$49$43,98325 claims
AbbVieLinzess, Namzaric$825$27,24045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Hamilton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →